139 related articles for article (PubMed ID: 36789739)
1. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
Lowry KP; Ichikawa L; Hubbard RA; Buist DSM; Bowles EJA; Henderson LM; Kerlikowske K; Specht JM; Sprague BL; Wernli KJ; Lee JM
Cancer; 2023 Apr; 129(8):1173-1182. PubMed ID: 36789739
[TBL] [Abstract][Full Text] [Related]
2. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
4. Five-year risk of interval-invasive second breast cancer.
Lee JM; Buist DS; Houssami N; Dowling EC; Halpern EF; Gazelle GS; Lehman CD; Henderson LM; Hubbard RA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25904721
[TBL] [Abstract][Full Text] [Related]
5. Risk of second breast cancer according to estrogen receptor status and family history.
Bouchardy C; Benhamou S; Fioretta G; Verkooijen HM; Chappuis PO; Neyroud-Caspar I; Castiglione M; Vinh-Hung V; Vlastos G; Rapiti E
Breast Cancer Res Treat; 2011 May; 127(1):233-41. PubMed ID: 20878464
[TBL] [Abstract][Full Text] [Related]
6. Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.
Lee JM; Abraham L; Lam DL; Buist DSM; Kerlikowske K; Miglioretti DL; Houssami N; Lehman CD; Henderson LM; Hubbard RA
J Clin Oncol; 2018 Jul; 36(20):2070-2077. PubMed ID: 29718790
[TBL] [Abstract][Full Text] [Related]
7. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
9. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
Nichols HB; Berrington de González A; Lacey JV; Rosenberg PS; Anderson WF
J Clin Oncol; 2011 Apr; 29(12):1564-9. PubMed ID: 21402610
[TBL] [Abstract][Full Text] [Related]
10. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
12. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status.
Schonfeld SJ; Curtis RE; Anderson WF; Berrington de González A
Cancer Causes Control; 2012 Oct; 23(10):1721-8. PubMed ID: 22918549
[TBL] [Abstract][Full Text] [Related]
13. Declining second primary ovarian cancer after first primary breast cancer.
Schonfeld SJ; Berrington de Gonzalez A; Visvanathan K; Pfeiffer RM; Anderson WF
J Clin Oncol; 2013 Feb; 31(6):738-43. PubMed ID: 23284037
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
15. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
[TBL] [Abstract][Full Text] [Related]
16. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
Ramin C; Veiga LHS; Vo JB; Curtis RE; Bodelon C; Aiello Bowles EJ; Buist DSM; Weinmann S; Feigelson HS; Gierach GL; Berrington de Gonzalez A
Breast Cancer Res; 2023 May; 25(1):50. PubMed ID: 37138341
[TBL] [Abstract][Full Text] [Related]
17. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).
Tarone RE; Chu KC
Cancer Causes Control; 2002 Feb; 13(1):7-14. PubMed ID: 11899120
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer.
Buist DS; Abraham LA; Barlow WE; Krishnaraj A; Holdridge RC; Sickles EA; Carney PA; Kerlikowske K; Geller BM;
Breast Cancer Res Treat; 2010 Dec; 124(3):863-73. PubMed ID: 20700648
[TBL] [Abstract][Full Text] [Related]
19. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
Dignam JJ; Wieand K; Johnson KA; Fisher B; Xu L; Mamounas EP
J Natl Cancer Inst; 2003 Oct; 95(19):1467-76. PubMed ID: 14519753
[TBL] [Abstract][Full Text] [Related]
20. Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use: A Report From the Childhood Cancer Survivor Study.
Veiga LH; Curtis RE; Morton LM; Withrow DR; Howell RM; Smith SA; Weathers RE; Oeffinger KC; Moskowitz CS; Henderson TO; Arnold MA; Gibson TM; Leisenring WM; Neglia JP; Turcotte LM; Whitton JA; Robison LL; Armstrong GT; Inskip PD; Berrington de Gonzalez A
JAMA Pediatr; 2019 Dec; 173(12):1171-1179. PubMed ID: 31657853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
